Evidence map›Paper›PMID 38311878›Full record

ArticleESC heart failure2024

Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort.

Johan Sundström, Johan Ärnlöv, Stelios Karayiannides, Johan Bodegard, Karolina Ersmark, Stefan Gustafsson, Thomas Cars, Maria K Svensson, Anna Norhammar

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Johan SundströmDepartment of Medical Sciences, Uppsala University, Entrance 40, 5th Floor, 75185, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-2247-8454
Johan ÄrnlövDivision of Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Stelios KarayiannidesDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Johan BodegardCardiovascular, Renal and Metabolism, Medical Department, BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden.
Karolina ErsmarkCardiovascular, Renal and Metabolism, Medical Department, BioPharmaceuticals, AstraZeneca, Stockholm, Sweden.
Stefan GustafssonSence Research AB, Uppsala, Sweden.
Thomas CarsSence Research AB, Uppsala, Sweden.
Maria K SvenssonDepartment of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden.
Anna NorhammarCardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Uppsala University · SEAstraZeneca (Italy) · ITAstraZeneca (South Korea) · KRDalarna University · SEDiabetes Australia · AUKarolinska Institutet · SE

Funding

AstraZeneca Mölndal
6 · The paper itself

Abstract

aimsThis study aimed to characterize a contemporary population with subtypes of incident or prevalent heart failure (HF) based on reduced (HFrEF), mildly reduced, or preserved (HFpEF) left ventricular ejection fraction (LVEF) and to assess how outcomes, healthcare, treatments, and healthcare costs vary between each subtype of incident HF. METHODS AND

resultsUsing Swedish data from the CardioRenal and Metabolic disease Heart Failure (CaReMe HF) study, updated to cover a more recent time period, this population-based study characterized patients from Stockholm County, Sweden, with incident HF (patients with a first HF diagnosis between 1 January 2015 and 31 December 2019) or prevalent HF (patients with a first HF diagnosis before 1 January 2020). Patients with incident HF had LVEF measured by echocardiography within ±90 days of their first HF diagnosis, and patients with prevalent HF within 5 years prior to the index date. The 13 375 patients with prevalent HF (39.2% women, mean age 73.9 years) had multiple comorbidities (cardiovascular diseases, chronic kidney disease, diabetes, and cancer). These were already highly prevalent at the time of the first HF diagnosis in the 8042 patients with incident HF (40.5% women, mean age 72.3 years). Patients with incident HFpEF received less specialist HF care at outpatient secondary care facilities following their first HF diagnosis than those with incident HFrEF. Patients with HFrEF had higher risks of complications and exerted a higher burden, in terms of care for and costs of HF, on the healthcare system.

conclusionsThis study of contemporary patients with incident HF demonstrates that those with HFpEF and HFrEF differ considerably in terms of clinical presentation, prognosis, and care, highlighting a potential to improve HF outcomes.

Indexed as

Heart FailureStroke VolumeVentricular Function, LeftAgedAged, 80 and overEchocardiographyFemaleFollow-Up StudiesHumansIncidenceMalePrevalencePrognosisSwedenHeart failureHFmrEFHFpEFHFrEFLeft ventricular ejection fraction

Identifiers

PMID38311878
PMCPMC11098668
OpenAlexW4391610648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.